The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

"Patients with anti-AQP4-Ab may basically need long-term relapse prevention, because they surely experience much higher relapse activity, with much worse neurological disturbance…In MOGAD patients, ...

Density loss in the optic nerve head capillary could lead to a faster rate of visual field progression as well as an increased risk of developing event progression. Glaucoma is best managed through ...

In the specialized fields of ophthalmologyand optometry, doctors measure sight by having you focus on a central point while keeping your head still. You’ll also be able to see above and below the ...